Type III systemic allergic reaction to natalizumab

Archives of Neurology

Volumn 65, Issue 6, 2008, Pages 851-852

  Leussink, Verena I ^b   Lehmann, Helmar C ^b   Hartung, Hans Peter ^b   Gold, Ralf ^b   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIMETINDENE; DRUG ANTIBODY; INTERFERON BETA SERINE; NATALIZUMAB;

ADULT; ALLERGIC REACTION; ANAMNESIS; ANAPHYLAXIS; BODY RASH; CASE REPORT; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; IMMEDIATE TYPE HYPERSENSITIVITY; LETTER; MULTIPLE SCLEROSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PRURITUS; SERODIAGNOSIS; TYPE III SYSTEMIC ALLERGIC REACTION;

EID: 45149130168     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.6.851-b     Document Type: Letter

References (3)

1. Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kümpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007;64(9):1331-1333.
2. Kieseier BC, Wiendl H, Hemmer B, Hartung HP. Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol. 2007;20(3):286-293.
3. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.